Semaglutide.
Semaglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist, an acylated, structurally modified analog of the native incretin hormone GLP-1, engineered for once-weekly (injectable) or daily (oral) dosing through albumin binding and resistance to DPP-4 degradation.
Semaglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist, an acylated, structurally modified analog of the native incretin hormone GLP-1, engineered for once-weekly (injectable) or daily (oral) dosing through albumin binding and resistance to DPP-4 degradation. Semaglutide is fda-approved, and PepCue grades its published evidence S tier (95/100). Also known as Ozempic · Wegovy. This is a research reference, not medical or dosing advice.
What it is
Semaglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist, an acylated, structurally modified analog of the native incretin hormone GLP-1, engineered for once-weekly (injectable) or daily (oral) dosing through albumin binding and resistance to DPP-4 degradation. It is a fully approved prescription medicine marketed as Ozempic and Rybelsus (type 2 diabetes) and Wegovy (chronic weight management and, more recently, cardiovascular risk reduction). It is one of the most extensively studied peptide therapeutics in modern medicine, with large dedicated cardiovascular- and liver-outcome trials.
How it works
Semaglutide binds and activates the GLP-1 receptor, a G-protein-coupled receptor expressed on pancreatic beta cells, the central nervous system, and elsewhere. In the pancreas it augments glucose-dependent insulin secretion and suppresses glucagon, lowering blood glucose with low intrinsic hypoglycemia risk because the effect is glucose-dependent. Centrally, it acts on hypothalamic and hindbrain appetite circuits to increase satiety and reduce food intake, and it slows gastric emptying; the combination drives weight loss. The molecule's C18 fatty-diacid side chain promotes albumin binding, which extends its half-life to roughly a week and underlies once-weekly dosing.
Mechanism pathways
Activating the GLP-1 receptor to enhance insulin release, slow gastric emptying, and reduce appetite.
Glucagon-like peptide-1 is an incretin hormone released from the gut after a meal. Its receptor is a class B G-protein-coupled receptor found on pancreatic beta cells, on stomach and gut tissue, and on neurons in the hypothalamus and brainstem, including the area postrema. When the receptor is activated, three things happen at once. Beta cells become more responsive to glucose, so insulin secretion rises mainly when blood glucose is already elevated rather than continuously, which is why this class carries a lower intrinsic hypoglycaemia risk than insulin itself. The stomach empties more slowly, flattening the rise in glucose after eating and prolonging the sense of fullness. Central appetite circuits shift toward satiety, reducing the drive to eat between meals. Glucagon secretion is also suppressed when glucose is high. Many compounds target this receptor because native GLP-1 is degraded within minutes by dipeptidyl peptidase-4. Almost every design problem in the class is a half-life problem, and the answers differ. Some analogs attach a fatty-acid chain so the molecule binds albumin and circulates far longer. Others alter the amino acids around the cleavage site so the enzyme cannot act. These structural choices set how often a compound is given and how steeply blood levels rise and fall, which in turn shapes how much nausea a person experiences during the early adjustment period. The class also splits by how many receptors a molecule touches. Pure GLP-1 agonists engage this pathway alone. Dual and triple agonists add GIP, glucagon, or amylin activity on top of it, and combination products pair a GLP-1 agonist with a separate molecule. In every case the GLP-1 arm remains the backbone of the metabolic effect. Of all the pathways described on this site, this one has the strongest and most mature clinical footing. Several GLP-1 receptor agonists are approved medicines for type 2 diabetes, for obesity, or both, and the mechanism has been characterised in humans rather than inferred from animal work. That does not make every molecule in the class equivalent. Some listed here are still investigational, and their receptor activity being well understood says nothing about whether their particular formulation, purity, or long-term profile has been established.
The evidence
Human evidence is exceptionally strong and trial-backed rather than preclinical. The STEP 1 randomized trial (NEJM 2021, PMID 33567185) showed substantial, clinically meaningful weight loss versus placebo in adults with overweight/obesity without diabetes. SUSTAIN-6 (NEJM 2016, PMID 27633186) demonstrated reduced major adverse cardiovascular events in type 2 diabetes, and SELECT (NEJM 2023, PMID 37952131) showed a significant reduction in cardiovascular death, myocardial infarction, or stroke in people with obesity and established cardiovascular disease but without diabetes. The phase 3 ESSENCE trial (NEJM 2025, PMID 40305708) reported improvement in metabolic dysfunction-associated steatohepatitis (MASH). A documented limitation: the STEP 1 extension (Diabetes Obes Metab 2022, PMID 35441470) showed substantial weight regain after discontinuation, indicating benefits depend on continued use.
The evidence, in brief
A GLP-1 receptor agonist with large randomized human trials behind it. The STEP program studied it for chronic weight management and SUSTAIN for type-2 diabetes; it is FDA-approved (Wegovy, Ozempic). It has the strongest weight/glucose evidence of any compound in this space, with well-documented GI side effects and the need for ongoing use.
- Wilding JPH et al.: Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1)N Engl J Med, 2021 (PMID 33567185)
- Wegovy / Ozempic (semaglutide): FDA prescribing informationFDA / DailyMed
Evidence maturity
An evidence-only reading: approval status, human vs preclinical data, mechanism and safety. Popularity never raises it. Research file #056
Approved or strong, consistent human evidence.
FDA-approved for a specific indication: the strongest lane.
Claim receipts
Popular claims about Semaglutide, checked against the state of the evidence. The verdict describes evidence maturity, never an invented study result.
Backed by large randomized human trials in obesity and overweight populations, the strongest lane of evidence.
It improves glycemic control and is approved for T2D, but it manages rather than cures the disease.
Longevity benefit is an extrapolation; it is not an approved or proven use.
Some lean-mass loss accompanies rapid weight loss, as with most weight-loss interventions; clinical significance is debated.
Safety profile
The most common documented adverse effects are gastrointestinal: nausea, vomiting, diarrhea, and constipation, typically most pronounced early in treatment. Labeled warnings include a boxed warning for thyroid C-cell tumors based on rodent data (clinical relevance in humans remains uncertain), plus risks of pancreatitis, gallbladder disease, acute kidney injury from dehydration, and diabetic retinopathy complications in susceptible patients. Reduced lean mass alongside fat loss, and weight regain after stopping, are recognized. Use of unregulated, compounded, or research-grade "semaglutide" sold outside the approved supply chain carries additional, poorly characterized risks of contamination, mislabeling, and dosing errors.
Compound notes
- Semaglutide is a GLP-1 receptor agonist, an incretin mimetic that enhances glucose-dependent insulin secretion, slows gastric emptying, and reduces appetite.
- It is FDA-approved (brands include Ozempic, Wegovy, Rybelsus) for type-2 diabetes and chronic weight management, backed by large human trials (the SUSTAIN and STEP programs).
- It has a long half-life of roughly one week, the pharmacologic basis for the once-weekly approved injectable formulations.
- Strong evidence for its approved uses; longevity/anti-aging extrapolations are not approved or proven.
- Common effects are gastrointestinal (nausea, etc.); see the FDA label for warnings and contraindications.
Regulatory status
Semaglutide is FDA-approved (not investigational): Ozempic and Rybelsus for type 2 diabetes with cardiovascular risk-reduction indications, and Wegovy for chronic weight management and for cardiovascular risk reduction in adults with cardiovascular disease and overweight/obesity. Oral semaglutide for chronic weight management and a MASH indication are the most recent regulatory developments.
Approved by the FDA for at least one indication.
By the numbers
- 01GLP-1 receptor agonist; an acylated analog of native GLP-1 engineered for extended half-life
- 02Sold as Ozempic and Rybelsus (diabetes) and Wegovy (weight management/CV risk)
- 03SELECT was the landmark trial showing cardiovascular benefit in obesity without diabetes
- 04Effects on weight are not durable after stopping: the STEP 1 extension showed significant regain
- 05Carries a boxed warning for thyroid C-cell tumors based on rodent studies
- 06Available in once-weekly injectable and daily oral formulations
Semaglutide: research formats
Choose the format you are researching to see route-specific notes.
Weekly SC injection. Wegovy titration is 5 steps over 16+ weeks.
FDA-approved semaglutide is available as Ozempic (diabetes, weekly) and Wegovy (weight, weekly), both as pen injectors for subcutaneous injection. The Wegovy titration schedule below is reproduced from the FDA prescribing information, a public regulatory fact.
Ozempic (diabetes indication) uses 0.5 mg, 1 mg, and 2 mg doses: a different schedule and dose ceiling from Wegovy. Do not interchange the two products.
If a dose step is not tolerated (persistent nausea/vomiting), the prescribing information allows delaying the next escalation. Your prescriber decides timing.
Sources
Every factual claim above resolves to a real, published source.
- Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1)New England Journal of Medicine, 2021, PMID 33567185
- Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT)New England Journal of Medicine, 2023, PMID 37952131
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6)New England Journal of Medicine, 2016, PMID 27633186
- Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis (ESSENCE)New England Journal of Medicine, 2025, PMID 40305708
Cite this page
PepCue. “Semaglutide: the evidence.” PepCue, reviewed June 1, 2026. https://www.pepcue.app/p/semaglutide.
Log your doses, run the vial math, and keep a provider-ready record in PepCue.